Skip to content

Study · Non-randomized trial · n = 65 · 1998

7 results

The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg.

Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R

Human reproduction (Oxford, England)1 Sept 1998Cited by 95 (Europe PMC)

PMID9806259 (opens in a new tab)DOI10.1093/humrep/13.9.2411 (opens in a new tab)PepBankPUB-09806259
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In IVF patients, LH decreases did not differ between cetrorelix 2 mg and 3 mg.

    In plain wordsIn IVF patients, LH decreases did not differ between cetrorelix 2 mg and 3 mg.

    Peptide
    Cetrorelix
    Outcome
    No significant changeLH decrease
    Study

    n = 65

    Comparator
    Cetrorelix 3 mg
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    2 mg · single administrationAs given in this study (human).

    Source sentences

    Summary
    No difference was observed in the decrease in LH and in oestradiol secretion between the 3 and the 2 mg groups, but the LH secretion was suppressed for a shorter time in the 2 mg group.
    3 context sentences
    Summary · context
    We compared in this study the results of a single administration of 3 versus 2 mg Cetrorelix in 65 patients undergoing ovarian stimulation and in-vitro fertilization (IVF).
    Summary · context
    The GnRH antagonist (Cetrorelix) was non-randomly administered at a dose of 3 mg (34 patients) or 2 mg (32 patients) on day 8 of the stimulation cycle.
    Summary · context
    In the case of slow follicular development, the injection was delayed until oestradiol reached 400 pg/ml.
  2. 02HumanNon-randomized trialEfficacy outcome

    In IVF patients, oestradiol secretion did not differ between cetrorelix 2 mg and 3 mg.

    In plain wordsIn IVF patients, oestradiol secretion did not differ between cetrorelix 2 mg and 3 mg.

    Peptide
    Cetrorelix
    Outcome
    No significant changeOestradiol secretion
    Study

    n = 65

    Comparator
    Cetrorelix 3 mg
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    2 mg · single administrationAs given in this study (human).

    Source sentences

    Summary
    No difference was observed in the decrease in LH and in oestradiol secretion between the 3 and the 2 mg groups, but the LH secretion was suppressed for a shorter time in the 2 mg group.
    3 context sentences
    Summary · context
    We compared in this study the results of a single administration of 3 versus 2 mg Cetrorelix in 65 patients undergoing ovarian stimulation and in-vitro fertilization (IVF).
    Summary · context
    The GnRH antagonist (Cetrorelix) was non-randomly administered at a dose of 3 mg (34 patients) or 2 mg (32 patients) on day 8 of the stimulation cycle.
    Summary · context
    In the case of slow follicular development, the injection was delayed until oestradiol reached 400 pg/ml.
  3. 03HumanNon-randomized trialEfficacy outcome

    In IVF patients given cetrorelix 3 mg, no LH surge occurred.

    In plain wordsIn IVF patients given cetrorelix 3 mg, no LH surge occurred.

    Peptide
    Cetrorelix
    Outcome
    Not applicableLH surge at 3 mg
    Study

    n = 34

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3 mg · single administrationAs given in this study (human).

    Source sentences

    Summary
    No LH surge was observed in the 3 mg group, while one surge (3%) and one significant rise in LH were observed in the 2 mg group.
    3 context sentences
    Summary · context
    We compared in this study the results of a single administration of 3 versus 2 mg Cetrorelix in 65 patients undergoing ovarian stimulation and in-vitro fertilization (IVF).
    Summary · context
    The GnRH antagonist (Cetrorelix) was non-randomly administered at a dose of 3 mg (34 patients) or 2 mg (32 patients) on day 8 of the stimulation cycle.
    Summary · context
    In the case of slow follicular development, the injection was delayed until oestradiol reached 400 pg/ml.
  4. 04HumanNon-randomized trialEfficacy outcome

    In IVF patients given cetrorelix 2 mg, one LH surge occurred (3%).

    In plain wordsIn IVF patients given cetrorelix 2 mg, one LH surge occurred (3%).

    Peptide
    Cetrorelix
    Outcome
    Not applicableLH surge at 2 mg
    Study

    n = 32

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    2 mg · single administrationAs given in this study (human).

    Measurements

    LH surge count
    1 patient
    2 mg
    LH surge rate
    3%
    2 mg

    Source sentences

    Summary
    No LH surge was observed in the 3 mg group, while one surge (3%) and one significant rise in LH were observed in the 2 mg group.
    3 context sentences
    Summary · context
    We compared in this study the results of a single administration of 3 versus 2 mg Cetrorelix in 65 patients undergoing ovarian stimulation and in-vitro fertilization (IVF).
    Summary · context
    The GnRH antagonist (Cetrorelix) was non-randomly administered at a dose of 3 mg (34 patients) or 2 mg (32 patients) on day 8 of the stimulation cycle.
    Summary · context
    In the case of slow follicular development, the injection was delayed until oestradiol reached 400 pg/ml.
  5. 05HumanNon-randomized trialEfficacy outcome

    In IVF patients given cetrorelix 2 mg, one significant LH rise occurred.

    In plain wordsIn IVF patients given cetrorelix 2 mg, one significant LH rise occurred.

    Peptide
    Cetrorelix
    Outcome
    IncreaseSignificant LH rise at 2 mg
    Study

    n = 32

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    2 mg · single administrationAs given in this study (human).

    Measurements

    significant LH rise count
    1 rise
    2 mg group

    Source sentences

    Summary
    No LH surge was observed in the 3 mg group, while one surge (3%) and one significant rise in LH were observed in the 2 mg group.
    3 context sentences
    Summary · context
    We compared in this study the results of a single administration of 3 versus 2 mg Cetrorelix in 65 patients undergoing ovarian stimulation and in-vitro fertilization (IVF).
    Summary · context
    The GnRH antagonist (Cetrorelix) was non-randomly administered at a dose of 3 mg (34 patients) or 2 mg (32 patients) on day 8 of the stimulation cycle.
    Summary · context
    In the case of slow follicular development, the injection was delayed until oestradiol reached 400 pg/ml.
  6. 06HumanNon-randomized trialEfficacy outcome

    In IVF patients, cetrorelix 2 mg suppressed LH for a shorter time than 3 mg.

    In plain wordsIn IVF patients, cetrorelix 2 mg suppressed LH for a shorter time than 3 mg.

    Peptide
    Cetrorelix
    Outcome
    DecreaseDuration of LH suppression
    Study

    n: not reported in source

    Comparator
    Cetrorelix 3 mg
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    2 mg · single administrationAs given in this study (human).

    Source sentences

    Summary
    No difference was observed in the decrease in LH and in oestradiol secretion between the 3 and the 2 mg groups, but the LH secretion was suppressed for a shorter time in the 2 mg group.
    3 context sentences
    Summary · context
    We compared in this study the results of a single administration of 3 versus 2 mg Cetrorelix in 65 patients undergoing ovarian stimulation and in-vitro fertilization (IVF).
    Summary · context
    The GnRH antagonist (Cetrorelix) was non-randomly administered at a dose of 3 mg (34 patients) or 2 mg (32 patients) on day 8 of the stimulation cycle.
    Summary · context
    In the case of slow follicular development, the injection was delayed until oestradiol reached 400 pg/ml.
  7. 07HumanNon-randomized trialEfficacy outcome

    In IVF patients, IVF results did not differ significantly between cetrorelix 2 mg and 3 mg.

    In plain wordsIn IVF patients, IVF results did not differ significantly between cetrorelix 2 mg and 3 mg.

    Peptide
    Cetrorelix
    Outcome
    No significant changeIVF results
    Study

    n: not reported in source

    Comparator
    Cetrorelix 3 mg
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    2 mg · single administrationAs given in this study (human).

    Source sentences

    Summary
    No significant difference was observed in IVF results in the two groups of patients.
    3 context sentences
    Summary · context
    We compared in this study the results of a single administration of 3 versus 2 mg Cetrorelix in 65 patients undergoing ovarian stimulation and in-vitro fertilization (IVF).
    Summary · context
    The GnRH antagonist (Cetrorelix) was non-randomly administered at a dose of 3 mg (34 patients) or 2 mg (32 patients) on day 8 of the stimulation cycle.
    Summary · context
    In the case of slow follicular development, the injection was delayed until oestradiol reached 400 pg/ml.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.